Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Nordea Healthcare Seminar 2009
11 slides from Getinge Ab Class B's conference presentation, September 2009
Slide 1: Nordea Healthcare Seminar 2009
NORDEA HEALTHCARE SEMINAR 2009 JOHAN MALMQUIST, CEO
Slide 2: Getinge today
Getinge today Revenues*: SEK 24 billion Associates: 12 800 * Estimated revenues 2009 SEK GETINGE September 2009 2
Slide 3: Structural changes in the Getinge Group for improved earnings growth
Structural changes in the Getinge Group for improved earnings growth: • Increased exposure to therapeutic areas • Expanding recurring revenue base: from 25% 45% of total revenue • Increased exposure to faster growing emerging markets: from 15% 22% of total revenue GETINGE September 2009 3
Slide 4: Strategic cornerstones
Strategic cornerstones • Market leadership • Integrated solutions • Customer relationships Sterilization no 1 Disinfection no 1 Integrated Infection Control Patient Handling no 1 solutions Hygiene Systems no 1 Wound Care/TS no 2 Integrated solutions IPC / DVT no 1 for health care ergonomics Surgical
Slide 5: Group financial targets
Group financial targets • 15% year over year average growth of pre tax earnings • To reach and maintain an EBITA-margin of 18-19 % • Cash flow generation to sustain an external growth rate of 10 % GETINGE September 2009 5
Slide 6: We believe we can continue to outgrow our market by ~2% in coming year
We believe we can continue to outgrow our market by ~ 2% in coming year • Increased exposure to faster growing emerging markets • Sales synergies from recent acquisitions: Huntleigh, Cardiac & Vascular Surgery divisions and Datascope • Continued investments in product development has expanded our ma
Slide 7: We believe that we can continue to strengthen our operating margins
We believe that we can continue to strengthen our operating margins by: • Ongoing realization of cost synergies from recent acquisitions. Declining integration costs. • Improved cost position through supply chain enhancement • Exposure to product segments with higher profitability • Introduction of
Slide 8: Integration of Datascope and Cardiac and Vascular surgery divisions
Integration of Datascope • Cost synergies of 170 MSEK from 2010 onwards • Redundant HQ structure • US delisting • Merged sales companies • Revenue synergies from geographical and product complementarities Integration of Cardiac and Vascular surgery divisions • Cost synergies of 100 – 120 MSEK from 2
Slide 9: Innovation and product development has not been fully exploited
Innovation and product development has not been fully exploited as a means of increasing growth across all business areas Cardiohelp. World’s Fusion graft. FLOW-i. Anaesthesia ED-flow. High smallest, portable Reinforced vessel system with superior capacity disinfector heart and lung implant made of
Slide 10: External growth will continue to play an important role
External growth will continue to play an important role in realizing both strategic and financial targets: Medical Systems • Cardiovascular: Vascular interventions and Cardiac assist • Surgical Workplaces: Surgical tools Extended Care • Therapeutic surfaces/wound care USA • Technology and product bo
Slide 11: Outlook 2009
Outlook 2009 • We expect revenues to grow organically by 2 – 3% • We expect pre tax profit to grow by 15% including integration costs of 200 MSEK relating to Datascope acquisition • We expect net gearing to improve significantly GETINGE September 2009 11